In this issue:
PET-guided treatment for advanced-stage Hodgkin’s lymphoma
CAR T-cells for refractory large B-cell lymphoma
Contribution of solid organ transplant to paediatric NHL burden
Outcomes of CML-BP in the TKI era
Clofarabine vs. fludarabine, with idarubicin and cytarabine, in new AML
Obinutuzumab vs. rituximab with CHOP in previously untreated DLBCL
Consolidation WBRT or SCT after high-dose chemoimmunotherapy in primary CNS lymphoma
Allogeneic HCT in intermediate-risk, triplenegative AML
Lenalidomide + rituximab in previously untreated FL
Please login below to download this issue (PDF)